WASHINGTON, Nov. 12, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November ...

Vanda Pharmaceuticals Inc (VNDA) reports a 23% revenue increase in Q3 2024, driven by Fanapt sales, despite a net loss and ...

Vanda Pharmaceuticals ( (VNDA) ) has released its Q3 earnings. Here is a breakdown of the information Vanda Pharmaceuticals presented to its ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2024 Earnings Call Transcript November 6, 2024 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.17.

Hello, and thank you for standing by. At this time, I would like to welcome you to the Q3 2024 Vanda Pharmaceuticals Inc. Earnings Conference Call. All lines has been placed on mute to prevent any ...

WASHINGTON (AP) — WASHINGTON (AP) — Vanda Pharmaceuticals Inc. (VNDA) on Wednesday reported a loss of $5.3 million in its third quarter. The Washington-based company said it had a loss of 9 ...

英为财情Investing.com - Vanda Pharmaceuticals (NASDAQ: VNDA )星期三发布了第三季度的财报，数据显示，公司营收逊于分析师的预期，每股收益超出了分析师的预期。 在该公司发布的最新财报中，公司每股收益为$-0.09，总营收为$47.7M，而此前英为财情Investing.com对分析师的调查显示，分析师预期该公司的营收为$50.75M，每股收益为$-0 ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-reports-third-quarter-2024-financial-results-302297977 ...

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns. Vanda Pharmaceuticals Inc (VNDA) has experienced a 7.96% rise in stock ...

The FDA has declined to approve Vanda Pharma's tradipitant for delayed gastric emptying (gastroparesis), prompting a furious response from the company. In a statement, the company says the FDA's ...